Drug Combination Details
| General Information of the Combination (ID: C59319) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Dacarbazine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Phase 2 | [1] | ||
|
Raji and Ramos Lymphoma
[ICD-11: 2A70]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | JNK2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | ||
| Ramos | CVCL_0597 | Burkitt lymphoma | Homo sapiens | |||
| Experimental
Result(s) |
Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone. | |||||
